Current Pharmaceutical Design
September 12, 2012
Rocío Martín‐Santos, José Alexandre S. Crippa, Albert Batalla et al.
288 citations
Delta-9-tetrahydrocannabinol (THC), but not cannabidiol (CBD), produces marked acute behavioral and physiological effects. In a randomized, double-blind, placebo-controlled trial with 16 healthy male volunteers, oral THC (10 mg) caused anxiety, dysphoria, positive psychotic symptoms, physical and mental sedation, subjective intoxication, and increased heart rate relative to placebo and CBD. CBD (600 mg) showed no differences from placebo on any symptomatic or physiological measure, indicating it is safe and well tolerated. The two main cannabis constituents thus have quite different acute effects.
Frontiers in Psychiatry
February 9, 2023
Kees Kramers, Arnt Schellekens, Metten Somers et al.
119 citations
A systematic review of psilocybin-assisted therapy for substance use disorders identified four clinical trials (six articles) involving 151 patients, with doses from 6 to 40 mg. Three studies focused on alcohol use disorder and one on tobacco use disorder. In a pilot study (n=10), heavy drinking days decreased significantly. In another single-arm study (n=31), 32% achieved complete alcohol abstinence over an average of 6 years. A double-blind, placebo-controlled RCT (n=95) found significantly fewer heavy drinking days with psilocybin versus placebo. In a pilot study (n=15), smoking abstinence at 26 weeks was 80% and at 52 weeks 67%. All trials indicated beneficial effects, but larger RCTs are needed.
Addiction Biology
March 3, 2016
Laura Blanco‐Hinojo, Jesus Pujol, Ben J. Harrison et al.
52 citations
Chronic cannabis use is associated with reduced motivation, and this study examined how it affects functional connectivity between the basal ganglia and brain regions involved in internal (frontal cortex) and external (sensory cortices) motivation signals. Resting-state fMRI in 28 chronic cannabis users and 29 controls showed that cannabis exposure attenuated the positive correlation between the striatum and limbic frontal-basal ganglia circuits, and attenuated the negative correlation between the striatum and the fusiform gyrus, which is important for recognizing significant visual features. These connectivity alterations were linked to lower arousal in response to affective pictures. Changes tended to normalize after one month of abstinence, indicating that cannabis impairs fine-tuning of the motivation system, but this effect is reversible.
CNS drugs
October 1, 2024
Anton Gomez-Escolar, Daniel Folch-Sanchez, Joanna Stefaniuk et al.
16 citations
Mental health disorders and substance use disorders (SUDs) contribute greatly to the global burden of disease. Psychedelics, including entactogens and dissociative substances, are being explored for SUD treatment but have less clinical evidence than for depression or PTSD. This narrative review discusses current research, therapeutic potential, and safety of psilocybin, LSD, ketamine, MDMA, and ibogaine in SUD treatment. It provides a balanced overview of potential benefits and harms in clinical settings, highlights the need for more research, and points out limitations and challenges to be addressed in future studies.
The Journal of Clinical Psychiatry
October 13, 2025
Pim B. van der Meer, Sebastiaan O Verboeket, Arjen J. C. Slooter et al.
NMDA receptor antagonists like ketamine may help treat catatonia. This systematic review evaluated the efficacy and safety of ketamine and esketamine for catatonia, finding that the available evidence suggests these drugs could be beneficial, but the data are limited and further research is needed to confirm their role.
Psychedelic Medicine
October 8, 2025
Pim B. van der Meer, Nout Schukking, Miranda G. Dik et al.
A systematic review of clinical trials found limited evidence that psychoactive tryptamines other than psilocybin and ibogaine are effective for treating substance use disorders. Four trials involving 176 patients with alcohol use disorder tested dipropyltryptamine and diethyltryptamine. Abstinence rates ranged from 10% to 38% at 26 weeks of follow-up, and severity of alcohol use did not differ between the tryptamine and control groups. Adverse effects were poorly reported. The review concludes that studies are scarce and show limited evidence for effectiveness in treating addictive disorders.